471270-60-7

Basic information

• Product Name: 2-(3-HYDROXYPROPYLAMINO)-6-(O-HYDROXYBENZYLAMINO)-9-ISOPROPYLPURINE
• Synonyms: 6-(2-HYDROXYBENZYLAMINO)-2-(3-HYDROXYPROPYLAMINO)-9-ISOPROPYLPURINE;P35;2-[[[2-[(3-Hydroxypropyl)amino]-9-(1-methylethyl)-9H-purin-6-yl]amino]methyl]-phenol;2-HYDROXY-BOHEMINE (HOB);GFRP;GTP cyclohydrolase 1 feedback regulatory protein;GTP cyclohydrolase I feedback regulatory protein;CDK INHIBITOR, P35
• CAS NO: 471270-60-7
• Molecular Formula: C18H24N6O2
• Molecular Weight: 356.42
• Product Categories: Heterocyclic Compounds;Bases & Related Reagents;Heterocycles;Inhibitors;Nucleotides
• Mol File: 471270-60-7.mol

Chemical Properties

• Appearance: /
• Density: 1.35
• Storage Temp.: -20°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 2-(3-HYDROXYPROPYLAMINO)-6-(O-HYDROXYBENZYLAMINO)-9-ISOPROPYLPURINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-HYDROXYPROPYLAMINO)-6-(O-HYDROXYBENZYLAMINO)-9-ISOPROPYLPURINE(471270-60-7)
• EPA Substance Registry System: 2-(3-HYDROXYPROPYLAMINO)-6-(O-HYDROXYBENZYLAMINO)-9-ISOPROPYLPURINE(471270-60-7)

Safety Data

• Hazardous Substances Data: 471270-60-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(3-HYDROXYPROPYLAMINO)-6-(O-HYDROXYBENZYLAMINO)-9-ISOPROPYLPURINE is used as a potent inhibitor for Cdk 1 and Cdk 2 for its ability to inhibit the activity of these proteins, which play a crucial role in cell cycle regulation and are often dysregulated in cancer cells. This makes it a potential therapeutic agent for the treatment of various types of cancer.
Used in Biotechnology Industry:
2-(3-HYDROXYPROPYLAMINO)-6-(O-HYDROXYBENZYLAMINO)-9-ISOPROPYLPURINE is used as a research tool for studying the role of Cdk 1 and Cdk 2 in cell cycle regulation and their involvement in cancer development. Its antiproliferative and proapoptotic effects also make it a valuable compound for investigating the mechanisms underlying cell growth and death, which could lead to the development of novel therapeutic strategies for cancer treatment.
Used in Drug Development:
2-(3-HYDROXYPROPYLAMINO)-6-(O-HYDROXYBENZYLAMINO)-9-ISOPROPYLPURINE is used as a lead compound in the development of new drugs targeting Cdk 1 and Cdk 2, which could potentially offer more effective treatments for cancer patients with better safety profiles and fewer side effects compared to existing therapies.
Used in Drug Combination Strategies:
2-(3-HYDROXYPROPYLAMINO)-6-(O-HYDROXYBENZYLAMINO)-9-ISOPROPYLPURINE can be used in combination with other chemotherapeutic agents to enhance their efficacy and overcome drug resistance in cancer treatment. Its ability to induce cell cycle arrest and apoptosis may synergize with the effects of other drugs, leading to improved therapeutic outcomes for patients with advanced or refractory cancers.

Upstream product

• 156-87-6 propan-1-ol-3-amine 
• 500568-72-9 2-[(2-chloro-9-isopropyl-9H-purin-6-ylamino)-methyl]-phenol 
• 203436-45-7 2,6-dichloro-9-isopropyl-9H-purine 
• 5451-40-1 2,6 dichloropurine 
• 932-30-9 2-Hydroxybenzylamine 

Relevant articles and documents

Synthesis and biological activity of olomoucine II.

Based on our previous experiences with synthesis of purines, novel 2,6,9-trisubstituted purine derivatives were prepared and assayed for the ability to inhibit CDK1/cyclin B kinase. One of newly synthesized compounds designated as olomoucine II, 6-[(2-hydroxybenzyl)amino]-2-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine, displays 10 times higher inhibitory activity than roscovitine, potent and specific CDK1 inhibitor. Olomoucine II in vitro cytotoxic activity exceeds purvalanol A, the most potent CDK inhibitor, as it kills the CEM cells with IC(50) value of 3.0 microM.

In vitro biotransformation of 2,6,9-trisubstituted purine-derived cyclin-dependent kinase inhibitor bohemine by mouse liver microsomes

1. Biotransformation pathways of the cyclin-dependent kinase inhibitor 6-benzylamino-2-(3-hydroxypropylamino)-9-isopropylpurine (bohemine) by mouse liver microsomes in vitro were investigated. 2. Metabolite profiles of [8-3H]-labelled bohemine were established by TLC/3H-autoradiography and enzymatic and MS analyses were used to elucidate the chemical structures of the metabolites. The structures of the main primary metabolites were confirmed by synthesis of authentic compounds. 3. A schema of the primary NADPH-dependent pathways has been proposed involving N2- and N9-dealkylation, N6-debenzylation, aromatic hydroxylation, and C2 side chain oxidation of bohemine. Three of the primary metabolites detected, 6-(benzylamino)-2-(3-hydroxypropylamino)purine (M4), 6-amino-2-(3-hydroxypropylamino)-9-isopropylpurine (M5) and 6-(4-hydroxybenzylamino)-2-(3-hydroxypropylamino)-9-isopropylpurine (M6), all retaining their parent primary hydroxyl group, were subsequently shown to be converted, by a liver cytosolic NAD+-dependent system, into their corresponding carboxylic acids. M6 was subject to microsomal glycosidations requiring UDP-sugar donors. NADPH-dependent conversion of M6 into M5 by microsomes was also demonstrated. 4. Cytochrome P450 (CYP) enzymes-selective inhibitors were used to identify CYPs involved in bohemine biotransformation. The findings suggested that CYP2a and CYP3a substantially contributed to the NADPH-dependent bohemine transformation in vitro. 5. The findings will facilitate experiments designed to dissect enzymatic systems catalysing clearance of C2,C6,N9-trisubstituted purine compounds from mammalian tissues.